PSS22 A Cost-Effectiveness Analysis of Off-Label Biologics to Treat Sarcoid Posterior Uveitis Versus Standard of Care- Comparing Infliximab to Methotrexate and Systemic Steroids
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1487
https://www.valueinhealthjournal.com/article/S1098-3015(11)03049-X/fulltext
Title :
PSS22 A Cost-Effectiveness Analysis of Off-Label Biologics to Treat Sarcoid Posterior Uveitis Versus Standard of Care- Comparing Infliximab to Methotrexate and Systemic Steroids
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)03049-X&doi=10.1016/j.jval.2011.08.1487
First page :
A505
Section Title :
Sensory Systems Disorders
Open access? :
No
Section Order :
1438